(Q37419812)

20 August 2017

1 reference

title

Thrombolytic therapy for deep vein thrombosis: potential application of plasmin (English)

1 reference

20 August 2017

0 references

1 reference

1 reference

Victor J Marder

1

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

123 Suppl 4

1 reference

20 August 2017

page(s)

S56-61

1 reference

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

1 reference

7 January 2021

A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Thrombolytic therapy in thrombosis: a National Institutes of Health consensus development conference

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

The Use of Thrombolytic Agents: Choice of Patient, Drug Administration, Laboratory Monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Clinical and experimental studies on fibrinolytic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Fibrinolysis and fibrinolytic activity in man

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

1 reference

7 January 2021

ENZYMATIC CLOT DISSOLUTION IN MAN: A NEW THERAPEUTIC APPROACH.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Structure and function of the plasminogen/plasmin system

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Refolding, purification, and activation of miniplasminogen and microplasminogen isolated from E. coli inclusion bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Disulfide structure of alfimeprase: a recombinant analog of fibrolase

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

A first-in-human phase I trial of locally delivered human plasmin for hemodialysis graft occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Development of catheter-directed intrathrombus thrombolysis with plasmin for the treatment of acute lower extremity arterial occlusion

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Effect of thromboxane synthase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Recombinant Tissue Plasminogen Activator for the Treatment of Lower Extremity Peripheral Vascular Occlusive Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Clinical risks of thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical t

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2809%2970145-8

7 January 2021

10.1016/S0049-3848(09)70145-8

Identifiers

DOI

1 reference

20 August 2017

1 reference